Main Article

Higher reimbursement rates and a demand for multiplex testing and workflow improvements are driving the global molecular diagnostic testing market to an estimated $5.5 billion dollars this year and a projected $10 billion in 2010. Analysis of revenue per requisition at commercial labs in 2007 reveals the higher reimbursement levels of these tests are leading many of these labs to put more focus on this business area in the future (see graph). For example, while molecular diagnostic testing was only comprising 3 percent of LabCorp’s (Burlington, N.C.) volumes in 2002, it was contributing 17 percent to its revenues. Currently, the company is said to derive 22 percent of its revenue from genomic and esoteric testing and is hoping this will increase to 40 percent in the next few years.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

June 2008 - Table of Contents

LIR June 2008 (full PDF issue)

Prices Dropping on Some DTC Genetic Tests as SACGHS Urges Tighter Regs

G-2 Predicts Global Mol Dx Industry to Reach $5.5 Billion in 2008, $8 Billion by 2010

Quest, LabCorp Revenue/Requisition Metrics Strengthen in Q1

LabCorp’s Partners With Siemens, Acquires Louisiana Lab

Cost and Profit Analysis Is Key to Capturing Revenue Potential of Mol Dx Lab

Q1 08 Lab Benchmark Data Reveal Psychemedics Still a Leader, Enzo Posts Gains

JVHL Teams With Clarient to Expand Cancer AP Menu

Orchid Cellmark Wins $30 Million Forensic Testing Contract in U.K.

Lab Stocks Continue to Post Gains in May, up 8% Over 5 Weeks

Economic Development Incentives Fuel Genzyme Genetics’s Staff Expansion in Santa Fe